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Background: All the children registered at the National Council for the Prevention and Treatment of Childhood
Cancer were analyzed. The rationale for this Federal Government Council is to financially support the treatment of
all children registered into this system. All patients are within a network of 55 public certified hospitals nationwide.
Methods: In the current study, data from 2007 to 2012 are presented for all patients (0–18 years) with a
pathological diagnosis of leukemia, lymphoma and solid tumors. The parameters analyzed were prevalence,
incidence, mortality, and abandonment rate.
Results: A diagnosis of cancer was documented in 14,178 children. The incidence was of 156.9/million/year (2012).
The median age was 4.9. The most common childhood cancer is leukemia, which occurs in 49.8% of patients
(2007–2012); and has an incidence rate of 78.1/million/year (2012). The national mortality rate was 5.3/100,000 in
2012, however in the group between 15 to 18 years it reaches a level of 8.6.
Conclusions: The study demonstrates that there is a high incidence of childhood cancer in Mexico. In particular,
the results reveal an elevated incidence and prevalence of leukemia especially from 0 to 4 years. Only 4.7% of these
patients abandoned treatment. The clinical outcome for all of the children studied improved since the
establishment of this national program.
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Of the biggest problems in developing nations is the high
incidence of childhood cancer is the high incidence and
the limited financial resources to develop a solid national
program for early diagnosis and management of these pa-
tients. We believe that pediatric cancer should now be
considered a global child health priority [1].
A worldwide childhood cancer survey in 2012 estimates
a higher incidence in developing countries (147,000
cancers/year) than in developed nations [2]. It is ex-
pected that this disease will continue growing because* Correspondence: riveraluna@terra.com.mx
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expanding.
Since 2010 in Mexico, cancer is the second leading
cause of mortality among children between 4 to 15 years
old [3]. This represents a current national health prob-
lem. There is a need to expand, fortify and improve early
diagnosis and treatment. As we have previously docu-
mented in developing countries including Mexico, there
is increasing evidence that the mortality rate is higher
than in developed countries [4]. This might be related to
a late referral to expert institutions for diagnosis and
early multidisciplinary treatment.
Close to half of the Mexican-children and adults-are
under a medical socialized program. This system con-
tains large hospitals and clinics nationwide and has been
run by the Federal Government Socialized Medicinentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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workers and their families had been able to access pooled-
prepayment options through public social security programs.
Meanwhile the other half (n: 51,823,314) of Mexicans,
including children and adults (2011) [4] has been pro-
gressively incorporating into a national health insurance
program. This universal health coverage is described as
“Popular Medical Insurance” (PMI) [5]. This program
was developed to provide access to a package of compre-
hensive health services-including childhood cancer treat-
ment with financial protection. This is done through a
national medical network from primary care clinics to
specialized medical hospitals certified by the Federal
Government. The program officially started in January
2005. However, it was not until 2007 that the full cover-
age was issued for all childhood cancers [6].
A referral system has been progressively developed
among this network to diagnose, treat and follow all of
these children. Currently 55 accredited medical institu-
tions nationwide with departments of pediatric hem/on-
cology are working fulltime. In each institution, there is
at least one certified pediatric hem/oncologist. The
population enrolled in this program belongs to the low-
est socio-economic levels, and their parents are mostly
non-salaried workers, rural residents and the unemployed.
The National Pediatric Cancer Registry under the aus-
pices of the Mexican Federal Government was started in
2006 but it was not until January 2007 that a national
registry appeared [7]. This registry includes all Mexican
children with cancer regardless of the medical system to
which they belong.
The purpose of this report is to present the prevalence,
incidence, mortality, and rate of abandonment in the
PMI program between 2007 and 2012.
Methods
An analysis was performed from 2007 to 2012 on all the
children from 0 to 18 years diagnosed with cancer registered
at the PMI program from all of the accredited institutions.
The diagnosis of leukemia was determined through
bone marrow aspiration for cytomorphology analysis,
immunophenotype, DNA index and cytogenetic. The
diagnosis of lymphomas and malignant solid tumors was
performed through biopsy and/or surgical resection for
pathology diagnosis. All institutional pathologic reports
were classified under the International Classification of
Childhood Cancer (ICCC-3) [8].
The medical data on each patient was obtained from the
National Commission on Health Social Protection (PMI)
which is the financial component of the program and from
the National Council for the Prevention and Treatment of
Childhood Cancer (CENSIA) headquarters which is the
technical and normative entity. Both strategies are under
the Federal Department of Health, and they work togethercollaboratively and exchange all of the patient information.
This data managing collaboration occurs through an
on-line process. The current work is a retrospective,
descriptive study at a national level and the data pre-
sented was analyzed from the data base program, no
approval from the Ethics Committee was required.
The variables obtained included in each patient’s hos-
pital registration: location of the treatment center, name,
address, date of birth, age, gender, diagnosis, stage of the
disease, follow up during treatment or under clinical sur-
veillance for more than 3 months, date of death and/or
abandonment. Only patients registered in this program
were included. Patients were subjected to standardized
treatment protocol regimens according to their respect-
ive diagnosis, and stage. All protocols were evaluated
previously by the National Council of Health [9] follow
by CENSIA [10]. The chemotherapy treatment protocols
were developed through a panel of experts that desig-
nated a national coordinator and associate coordinators.
Development of this protocols took place from 2004 to
2006. All of the treatment regimens were developed on
the basis of international cancer treatment protocols that
demonstrated solid therapeutic results. The scope of the
current study is to analyze exclusively the epidemio-
logical aspects of this population.
This descriptive work comprises patients from 55
accredited institutions registered from January 2007 to
December 2012. The institutional accreditation criteria
were applied through a methodical evaluation from the
Office of Medical Innovation and Medical Quality of the
National Health Department and medical personnel trained
for this type of task.
From a strategic standpoint, Mexico was divided into
6 geographical areas so as to have a physician supervis-
ing each area. The role of this specialist is to organize,
assist and solve all the problems connected to treatment
regimens and local institutional problems related to the
children with cancer.
Prevalence was defined as the number of children who
have been diagnosed with a type of cancer, at a given
year and expressed as the percentage of the disease in
Mexican children between 0 to 18 years and registered
in the period of time of the study [2]. The incidence rate
was defined as the total number of newly diagnosed cases
per year/the total population under 18 years who were-
registered with a Medical Policy at the PMI by 1 million
population/year (Table 1) [2]. Age-specific incidence was
defined as the total number of cases of a specific age
group/the total population registered in that age group by
1,000,000 population/year. The overall mortality rate was
determined as an absolute number of deceased patients/
100,000 persons/year [2].
All patients presented in this work study had a patho-
logical diagnosis of cancer, and were treated with a minimal
Table 1 Absolute number of children (0–18 years)
registered with a popular medical insurance health policy
and newly diagnosed children with cancer/year
Year of registration Population registered
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units.
The program started on January 5th 2005 [10], and the
number of original participating institutions was 16. At
the beginning only acute leukemia was introduced into
this program. However all childhood cancers were pro-
gressively included, until January 2007 after which all types
of childhood cancers were registered and treated under the
national protocols. Therefore, the current work includes
only cases collected from January 2007 to December 2012.
Descriptive statistical analysis was performed using
GraphPad Instant version 3.0.Results
From January 2007 to 2012 there were 14,178 patients
registered with cancer (Table 2). The most commonTable 2 Prevalence of PMI childhood and adolescent cancers






Leukemia 1,056 (52.4) 1,122 (50.3) 1,133 (49.5)
Lymphomas 207 (10.3) 206 (9.2) 244 (10.7)
Intracranial neoplasm’s 188 (9.3) 198 (8.9) 198 (8.7)
Germ cell tumors 53 (2.6) 91 (4.1) 118 (5.2)
Soft tissue sarcomas 108 (5.4) 110 (4.9) 95 (4.2)
Osteosarcoma 92 (4.6) 104 (4.7) 126 (5.5)
Retinoblastoma 75 (3.7) 97 (4.4) 70 (3.1)
Renal tumors 80 (4.0) 84 (3.8) 67 (2.9)
Miscellaneous reticular
neoplasm’s
40 (2.0) 47 (2.1) 58 (2.5)
Hepatic tumors 30 (1.5) 44 (2.0) 35 (1.5)
Neuroblastoma 39 (1.9) 46 (2.1) 54 (2.4)
Ewing tumor and related
sarcomas of bone
17 (0.8) 31 (1.4) 35 (1.5)
Other solid tumors 32 (1.6.) 49 (2.2) 54 (2.4)
Total n cases 2,017 2,229 2,287
International Classification of Childhood Cancers (ICCC-3)(7).cancer was leukemia (49.8%), followed by lymphoma
(9.9%) and central nervous system tumors (9.4%).
When the total cohort of children were grouped by
age, it showed that the highest incidence was in children
between 0–4 years and the lowest was 15 to 18 years
through these 6 years (Figure 1). In terms of gender,
males were predominately affected [7868 (55.5%)], while
the frequency was slightly lower in females [6310 (44.5%)],
with a ratio M: F of 1.2:1. Depending upon the type of
childhood malignancy males accounted for 54.4% of pa-
tients with acute leukemia, 54.2% with brain tumors and
64% of the lymphoma cases (both Hodgkin’s and non-
Hodgkin’s subtypes).
The national childhood cancer incidence rate in the PMI
program over the six years of this study has been increasing
(Table 3). In 2012 the incidence was 156.9/million. It was
taken into account that the population of Mexico increased
from 106,900,000 in 2007 to 113,336,538 in 2012 [3].
In 2012 the national population census reported
32,972,300 Mexicans between 0 to 18 years (37%).
However, only 17,014,321 of the eligible population
under 18 years was registered at the PMI program. In
the process of tumor classification, Langerhans-cell
histiocytosis was included as miscellaneous reticular
neoplasm-following the ICCC-3 pathologic classification.
The incidence of leukemia was 78.1/1,000,000/year
(2012). The prevalence of leukemia over the six years of the
current analysis was 49.8%. The predominance of acute
lymphoblastic leukemia was documented in all age groups;
(Table 4) in comparison with acute and chronic non-









1,204 (50.1) 1,222 (47.5) 1329 (49.7) 7,066 (49.8)
247 (10.3) 255 (9.9) 258 (9.6) 1,417 (9.9)
228 (9.5) 254 (9.9) 277 (10.3) 1,343 (9.4)
146 (6.1) 153 (6.0) 152 (5.6) 713 (5.0)
79 (3.3) 120 (4.7) 112 (4.1) 624 (4.4)
74 (3.1) 94 (3.7) 77 (2.8) 567 (3.9)
93 (3.9) 104 (4.0) 100 (3.7) 539 (3.8)
89 (3.7) 80 (3.1) 87 (3.2) 487 (3.4)
63 (2.6) 79 (3.1) 95 (3.5) 382 (2.6)
51 (2.1) 67 (2.6) 48 (1.7) 275 (1.9)
38 (1.6) 51 (2.0) 46 (1.7) 274 (1.9)
47 (2.0) 38 (1.5) 24 (0.8) 192 (1.3)
44 (1.8) 54 (2.1) 66 (2.4) 299 (2.1)




































Figure 1 Incidence by age group during 6 years of the study.
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and 47.8% of children presented with Hodgkin’s lymphoma;
this difference was not statistically significant.
This trend clearly indicates that the participation of
the PMI accredited institutions and their respective re-
gional coordinators had a beneficial effect on treatment
compliance. The national mortality rate/state of resi-
dence was from 5.8 in 2007, to 5.3 in 2012/100,000/year.Table 3 Incidence* of PMI childhood and adolescent
cancers
Diagnosis 2007 2008 2009 2010 2011 2012
Leukemia 69.9 73.4 73.1 75.3 75.6 78.1
Lymphomas 13.7 13.4 15.7 15.4 15.7 15.1
Intracranial neoplasm’s 12.4 12.9 12.7 14.2 15.7 16.2
Germ cell tumors 3.5 5.9 7.6 9.1 9.4 8.9
Soft tissue sarcomas 7.1 7.1 6.1 4.6 4.9 6.5
Osteosarcoma 6.0 6.8 8.1 4.7 6.2 4.5
Retinoblastoma 4.9 6.3 4.5 5.8 6.5 5.8
Renal tumors 5.2 5.4 4.3 5.5 5.0 5.1
Miscellaneous reticular
neoplasm’s
2.6 3.0 3.7 3.9 4.9 5.5
Hepatic tumors 1.9 2.8 2.2 2.3 3.1 2.8
Neuroblastoma 2.5 3.0 3.4 3.1 4.1 2.7
Ewing tumor and related
sarcomas of bone
1.1 2.0 2.2 2.9 2.3 1.4
Other solid tumors 2.1 3.2 3.4 2.7 3.3 3.8
Total incidence/year 133.5 145.8 146.2 150.3 159.2 156.9
*Incidence: total number of newly diagnosed cases per year/total population
under 18 years by 1,000,000 population/year.In this last year the lowest rate was in the group under
1 year at 2.5 and was the highest in the group of adoles-
cents between 15 to 18 with a rate of 8.6 (Table 5).
The percentage of patients who abandoned treatment
was 4.7%/year, the range was from 4.5% in 2012 to 5.2%
in 2007.
Discussion
The incidence of cancer in children under 18 is increasing
especially in developing countries including Mexico [11-14].
To address this problem, several key initiatives have been
established by the Mexican Federal Government, including
the development of the PMI which applies a diagonal ap-
proach to health insurance. Horizontal, population-based
coverage is provided for all public and community health
services. A package of essential health services is managed
at the state-level for all those enrolled with the PMI [5].Table 4 Prevalence of 7066 leukemia’s by age groups
registered in the PMI from 2007-2012
Type of leukemia 0-4 5-9 10-14 15-18 Total
n n n n n
(%) (%) (%) (%) (%)
Acute lymphoblastic
leukemia
2,346(40) 2,170(37) 762(13) 586(10) 5,864(83)
Acute myelogenous
leukemia
278(30) 195(21) 185(20) 269(29) 927(13.1)
Chronic myelocytic
leukemia
45(23) 54(27) 55(28) 44(22) 198(2.8)
Myelodysplastic
syndromes
8(10) 22(28) 24(32) 23(30) 77(1.0)
Total number 2,677 2,441 1,026 922 7,066
Table 5 *Mortality rate by geographical location and by
age groups in accredited pediatric cancer institutions
in 2012
State-rate <1 1-4 5-9 10-14 15-18
NORTHWEST STATES 5.0
1. Baja California 5.4 5.1 3.3 3.8 5.7 10.0
2. Baja California South 6.7 0.0 1.9 11.8 7.7 2.6
3. Chihuahua 5.5 4.0 5.4 4.8 2.9 11.6
4. Durango 3.1 6.0 2.2 1.2 3.4 4.9
5. Nayarit 3.7 4.6 4.4 0.9 4.6 4.6
6. Sinaloa 4.5 1.9 3.3 4.0 4.7 6.1
7. Sonora 6.6 1.9 6.1 5.5 4.1 12.9
NORTH EAST STATES 4.7
8. Coahuila 5.1 3.7 6.5 2.6 4.7 6.9
9. Nuevo León 4.7 3.5 5.7 3.4 4.1 5.5
10. San Luis Potosí 4.4 3.8 1.9 2.2 5.1 8.7
11. Tamaulipas 4.9 0.0 5.2 4.7 2.2 9.3
CENTRAL STATES 5.4
12. Aguascalientes 4.6 0.0 3.9 3.1 3.1 10.8
13. Colima 7.1 7.8 8.0 4.8 3.2 13.2
14. Guanajuato 5.5 3.5 4.2 4.5 5.1 8.4
15. Jalisco 6.3 4.8 5.1 4.6 5.2 11.1
16. Michoacán 4.8 5.6 4.2 4.1 2.9 7.8
17. Querétaro 5.3 2.7 3.4 5.8 4.2 8.0
18. Zacatecas 4.2 3.3 9.0 1.9 1.9 4.4
CENTRAL METROPOLITAN 5.1
19. Hidalgo 4.8 5.5 3.2 4.8 2.2 9.4
20. México 4.7 1.6 4.2 3.8 4.0 7.6
21. Mexico City 5.9 0.8 4.8 5.4 4.8 9.6
22. Tlaxcala 5.2 4.0 3.0 4.8 4.8 8.3
SOUTHERN STATES 5.4
23. Morelos 5.2 5.9 1.5 5.3 6.4 5.7
24. Oaxaca 5.4 3.7 5.9 4.2 4.6 7.1
25. Puebla 5.5 0.8 3.8 4.4 5.5 9.3
26. Veracruz 5.7 1.4 3.4 5.0 4.3 11.9
SOUTHEAST STATES 5.7
27. Campeche 6.1 6.1 3.0 2.4 12.3 4.0
28. Chiapas 5.7 1.8 7.8 3.5 3.8 9.1
29. Guerrero 3.9 4.1 4.4 2.4 3.1 5.8
30. Quintana Roo 5.7 0.0 7.7 5.0 4.5 6.2
31. Tabasco 7.7 2.2 8.8 8.8 4.9 8.2
32. Yucatán 5.1 0.0 4.6 4.9 3.2 8.7
NATIONAL RATE 5.3 2.5 4.7 4.2 4.3 8.6
*mortality rate by 100,000 children/year.
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pital accreditation and providing financial assistance to
each institution for the treatment of qualifying children
with cancer. These initiatives [14] also include the en-
dorsement of treatment protocols/guidelines, the supply
of hospital equipment to pediatric oncology units, tech-
nical and financial support for pediatric oncology training
programs [13]. By 2011, only 92/150 (61.3%) pediatric
hem/oncologists in Mexico were working in accredited
hospitals under the PMI program. Rigorous evaluation
processes have been underway since the PMI was estab-
lished, and the results are encouraging for childhood can-
cer. Adherence to treatment prior to the PMI program
was 48% in 2007 and by 2012 rose to 95%.
There were 35,591 children treated for cancer among
the 55 PMI accredited Mexican institutions during the
period of analysis, which included new patients (14,178)
plus 21,413 follow-up patients by the end of 2012. That
being said, a pediatric oncologist in the PMI program
treated an average of 392 patients in 6 years. In institu-
tions that have one pediatric oncologist for an entire
state, the burden of the patient load increases signifi-
cantly with the imperative to provide a continuously
high standard patient care. However, few institutions in
Mexico have as many as 8 pediatric oncologists on their
full-time staff. This national patient load is obviously
higher than recommended for develop countries.
In our current study, we report the findings from a lar-
ger number of patients from the Mexican PMI program
than the previous study [4]. This represents approxi-
mately more than half from the national cancer registry
including socialized medicine with their hospitals and in
the other side the PMI program. The number of children
with cancer registered in the PMI program is very sub-
stantial and merits further analysis, especially if these
children belong to the lowest socioeconomically de-
prived bracket of Mexicans. The national childhood can-
cer incidence [7] in Mexico in the year 2010 from the
PMI patients plus those registered in socialized public
healthcare systems accounted for 4653 patients with an
incidence of 145.5/million/year. The previously published
SEER data from the United States [15] has indicated an in-
cidence of childhood cancer (0–19 years) of 173.4/million
person/year. In our current study, we have found a higher
incidence in childhood cancers than previously published
[4] which indicate the need for a more vigorous national
public health program for this disease [1]. The active par-
ticipation of the federal government, which could include
providing additional funds to develop better equipped
medical institutions and promoting the training of certi-
fied pediatricians to enroll in pediatric oncology fellowship
programs, is required.
As outline before [2] the high prevalence of leukemia
deserves further research especially with the prevalent
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in Mexico and elsewhere to organophosphate-based pes-
ticides [16]. Other factors need to be taken into account,
including paternal smoking [17], fertilizers and proxim-
ity to oil fields [18] especially around the time of con-
ception. Exposure to early infections constitutes another
constant factor that is considered in the possible etiology
of acute leukemia of childhood especially in the very
young [19]. Another factor that might contribute to the
etiology of childhood leukemia is in-vitro fertilization,
which is reported to be associated with increased risk
of early onset of acute lymphoblastic leukemia in the
offspring [20].
According to the Mexican national statistics [3] from
112 million inhabitants, there are 50 million that live
below the poverty line. This fact, from the public health
point of view, should direct attention to the triangle of
poverty, malnutrition and early infections that most
likely play a very important role in the etiology and inci-
dence of childhood cancer in the PMI population. Re-
cent studies [21] have suggested that the incidence of
cancer among children living in poverty is much higher
than in more affluent populations. This deficiency might
be a factor that can account for the higher incidence of
acute lymphoblastic leukemia in comparison to those
children treated by the socialized healthcare systems in
Mexico, in which the socioeconomic and cultural level is
much higher.
Due to the improvement of national public health
measures, the incidence of perinatal diseases, malnutri-
tion, gastroenteritis and pneumonia have decreased the
pediatric mortality rate in Mexico very significantly,
allowing for children to reach an age which childhood
cancer is more common. It is ironic that the improved
survival rates in children with these diseases may be a
factor in the increased incidence rates of cancer. How-
ever, incidence and mortality rate are not necessarily
correlated in Mexico, as has been outlined [22], but the
standard of medical care is constantly improving and the
PMI program has had a very beneficial impact on the
prognosis for low-income pediatric cancer patients.
In 2004, the National Council of Health from the
Federal Health Department and a group of pediatric hem/
oncologists produced technical protocols for treating the
most commonly occurring childhood malignancies experi-
enced in Mexico. We formulate 26 treatment protocols
based on international treatment guidelines [9], which
included multidisciplinary treatment approaches for all
childhood cancers. One of the principal achievements of
this program is the progressive improvement of the overall
survival. We were able to identify 11 states in Mexico that
had an overall survival for all childhood malignancies be-
yond 72% versus 10 states in which the overall survival
was less than 65%. The possible explanation for this laterfinding is multifactorial and includes, limited number of
pediatric hem/oncologist in these areas, advanced and
complicated disease at diagnosis, some with small, space-
restricted units, low number of pediatric oncology nurses,
and a lack of full-time pediatric specialists available for
the multidisciplinary approach including surgeons, in-
tensive care specialists, and radiotherapists. Those institu-
tions that had the best survival rates are affiliated with
university hospitals and at least a residency program in
pediatrics and a training program in childhood cancer for
the nursing personnel.
Regarding mortality, we have been able to maintain a
similar rate from 2007 to 2012. However when com-
pared to other developing countries we need to work
harder to decrease the mortality even further [23-25]. A
very important finding is the high mortality rate in 2012
among adolescents from 15 to 18 years old. One of the
observations we have documented in this respect is that
more than half of these patients were very advanced or
had unfavorable prognostic signs when they arrived for
medical care of their cancer. There are multiple pos-
sible explanations for these findings and they deserve
to be investigated and reported in future scientific
publication.
The need to continue monitoring the treatment proto-
cols and avoiding violation of these regimens could
eventually lead to better results and a decrease in the
mortality rate. On a collegiate basis the protocols are re-
vised every 6 months among all participating institutions
and the Council of General Health of Mexico. Proper
modifications are performed in those instances where
there is a high rate of relapse and/or complications.
Chatenoud, et al. [26] reported a standardized mortal-
ity rate (per 100,000/year) of 6.45 and 5.42 among boys
and girls respectively in Mexico in the period from
2005–2006. However, in 2012 we documented a standard-
ized overall mortality rate of 5.3 without a significant dif-
ference between genders. We recognize that our mortality
rate is higher compared with other Latin-American coun-
tries [27-29] in spite of the PMI program. Mexican chil-
dren (<18 years) with cancer had an average lifespan of
10.8 years and therefore impede living on an average of
59.2 years [6], while in develop countries, the survival rate
in childhood cancer is higher and better [30]. It is import-
ant to direct our attention to pediatric oncology in devel-
oping nations. In most of our Latin-American countries
there is a failure to make an early diagnoses and, to a
lack of treatments regimens-clinical trials and inad-
equate health care systems [31,32]. Another point that
deserves to be mentioned is the continuous low rate of
abandonment that has been maintained during the six
years of this study and up to the present time, consist-
ent with observations that international studies have
eradicated this problem [32].
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The national childhood cancer registration in the PMI
program denotes a high prevalence and incidence among
Mexican children. The current experience demonstrates
that the creation of a cooperative treatment group for
childhood cancer in a developing nation can be accom-
plished through the efforts of a multidisciplinary approach.
The combination of horizontal coverage of personal health
services with a catastrophic fund makes it possible to offer
financial protection for childhood cancer, as well as invest-
ing in early detection and survivorship care. Our future
goal is to continue improving the treatment program and
therefore the outcome for these children. We believe that
children with cancer worldwide deserve a stronger focus
on their needs than they are currently receiving, especially
in resource-poor settings.
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